While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

Shares of AstraZeneca PLC AZN advanced 1.46% to £102.92 Thursday, on what proved to be an all-around positive trading session ...

AstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, and AstraZeneca stock rose despite a criminal probe in China.

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good ...

The data showed that Koselugo met its primary endpoint, demonstrating a statistically significant and clinically meaningful ...

Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating yesterday. Andrew Berens gave his rating based on several factors, including AstraZeneca’s ...

Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying ...

AstraZeneca's price plunge following a fraud investigation in China could be just the time to buy AZN stock as big picture ...

AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially ...

Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall ...

CORE EARNINGS PER SHARE: One of the Anglo-Swedish pharmaceutical major's preferred metrics, core EPS is expected to come in at $2.04 in the third quarter, according to a company-compiled consensus ...